First-in-class transactivator-free, doxycycline-inducible IL-18-engineered CAR-T cells for relapsed/refractory B cell lymphomas

• Main Authors: Pedro Justicia-Lirio (Author), María Tristán-Manzano (Author), Noelia Maldonado-Pérez (Author), Carmen Barbero-Jiménez (Author), Marina Cortijo-Gutiérrez (Author), Kristina Pavlovic (Author), Francisco J. Molina-Estevez (Author), Pilar Muñoz (Author), Ana Hinckley-Boned (Author), Juan R. Rodriguez-Madoz (Author), Felipe Prosper (Author), Carmen Griñán-Lison (Author), Saúl A. Navarro-Marchal (Author), Carla Panisello (Author), Julia Muñoz-Ballester (Author), Pedro A. González-Sierra (Author), Concha Herrera (Author), Juan A. Marchal (Author), Francisco Martín (Author)
• Format: Book
• Published: Elsevier, 2024-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Although chimeric antigen receptor (CAR) T cell therapy has revolutionized type B cancer treatment, efficacy remains limited in various lymphomas and solid tumors. Reinforcing conventional CAR-T cells to release cytokines can improve their efficacy but also increase safety concerns. Several strategi...